stockrowSmith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Return on equity
Smith & Nephew SNATS, Inc.'s return on equity over the twelve months to 30 June 2026 was 0.00%, down 11.8 percentage points from fiscal 2025 (11.8%). Over the past ten years it has ranged from 4.12% (fiscal 2022) to 19.8% (fiscal 2016); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 11.8% | 3.98 |
| FY2024 | 7.86% | 2.84 |
| FY2023 | 5.02% | 0.90 |
| FY2022 | 4.12% | (5.54) |
| FY2021 | 9.66% | 1.06 |
| FY2020 | 8.60% | (3.38) |
| FY2019 | 12.0% | (1.95) |
| FY2018 | 13.9% | (3.90) |
| FY2017 | 17.8% | (1.96) |
| FY2016 | 19.8% | 9.55 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PODD Insulet Corporation compare | 28.9% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| GMED Globus Medical, Inc. compare | 12.1% |
| PEN Penumbra, Inc. compare | 10.7% |
| SNN Smith & Nephew SNATS, Inc. | 0.00% |
| BRKR Bruker Corporation compare | −7.04% |
| TXG 10x Genomics compare | −9.40% |
| GKOS Glaukos Corporation compare | −22.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement